| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/14/2005 | CA2550650A1 Co-administration of dopamine-receptor binding compounds |
| 07/14/2005 | CA2550649A1 3-(4-piperidine-1ylmethyl-phenyl)-propion acid-phenylamide-derivatives and related compounds used in the form of mch antagonists (melanine concentrating hormone) for treating eating disorders |
| 07/14/2005 | CA2550435A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 07/14/2005 | CA2550432A1 Pharmaceutical compositions |
| 07/14/2005 | CA2550383A1 Methods and compositions for directing migration of neural progenitor cells |
| 07/14/2005 | CA2550375A1 Azabicyclic heterocycles as cannabinoid receptor modulators |
| 07/14/2005 | CA2550361A1 Compounds and methods for development of ret modulators |
| 07/14/2005 | CA2550352A1 Compounds for the inhibition of undesired cell proliferation and use thereof |
| 07/14/2005 | CA2550344A1 18-membered nitrobenzyl-substituted and aminobenzyl-substituted cyclohexadepsipeptides for controlling endoparasites, and method for the production thereof |
| 07/14/2005 | CA2550342A1 Effervescent preparation of a basic medicinal substance |
| 07/14/2005 | CA2550316A1 Immunoassays, haptens, immunogens and antibodies for anti-hiv therapeutics |
| 07/14/2005 | CA2549898A1 Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 07/14/2005 | CA2549652A1 Cd40 antibody formulation and methods |
| 07/14/2005 | CA2549638A1 Therapeutic combination for cognition enhancement and psychotic disorders |
| 07/14/2005 | CA2549606A1 Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
| 07/14/2005 | CA2549599A1 Pregabalin composition |
| 07/14/2005 | CA2549462A1 Self-microemulsifying drug delivery systems of a hiv protease inhibitor |
| 07/14/2005 | CA2548951A1 Kinase inhibitor phosphonate conjugates |
| 07/14/2005 | CA2548921A1 Novel derivatives of morphine-6-glucuronide, pharmaceutical compositions containing said derivatives, preparation method thereof and uses of same |
| 07/14/2005 | CA2548363A1 Pharmaceutical formulations of bisphosphonates |
| 07/14/2005 | CA2548357A1 Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiences |
| 07/14/2005 | CA2548353A1 Glucopyranosyloxy-substituted aromates, medicaments containing said compounds, the use thereof, and methods for producing the same |
| 07/14/2005 | CA2548326A1 Bicyclic heterocyclic p-38 kinase inhibitors |
| 07/14/2005 | CA2548318A1 Benzo-1, 4 diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof |
| 07/14/2005 | CA2548316A1 Preparation of r-5-(2-(2-ethoxyphenoxyetylamino)propyl)-2-methoxybenzenesulphonamide hydrochloride of high chemical |
| 07/14/2005 | CA2548313A1 Methods and compositions for the prevention and treatment of inflammatory diseases or conditions |
| 07/14/2005 | CA2548309A1 Aryl sulfonamide compounds and uses related thereto |
| 07/14/2005 | CA2548305A1 Use of alginate matrices to control cell growth |
| 07/14/2005 | CA2548146A1 Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
| 07/14/2005 | CA2548035A1 Cdk2 antagonists as short form c-maf transcription factor antagonists for treatment of glaucoma |
| 07/14/2005 | CA2547852A1 Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| 07/14/2005 | CA2547837A1 Polymorph of birb 796, a p38map kinase inhibitor |
| 07/14/2005 | CA2547645A1 Use of rotigotine for the treatment or prevention of dopaminergic neuron loss |
| 07/14/2005 | CA2546797A1 Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease |
| 07/14/2005 | CA2546147A1 Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| 07/14/2005 | CA2545324A1 Aminoglycoside antibiotics for use as vap-1/ssao inhibitors |
| 07/14/2005 | CA2507343A1 Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents |
| 07/13/2005 | EP1553123A1 Perfluoropolyether derivatives |
| 07/13/2005 | EP1553099A1 A riboflavin derivative and its manufacture and uses |
| 07/13/2005 | EP1553098A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 07/13/2005 | EP1553097A1 Quinazoline derivatives as angiogenesis inhibitors and intermediates therefore |
| 07/13/2005 | EP1553096A1 Pyrazole compounds |
| 07/13/2005 | EP1553094A1 Azulene derivatives and salts thereof |
| 07/13/2005 | EP1553092A1 Aralkyl formyl-alkyl piperazine derivatives and their uses as cerebral nerve protective agent |
| 07/13/2005 | EP1553091A1 Heteroaromatic pentacyclic compound and medicinal use thereof |
| 07/13/2005 | EP1553089A1 Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
| 07/13/2005 | EP1553087A1 Preventive and/or therapeutic drugs for inflammatory intestinal diseases |
| 07/13/2005 | EP1553085A1 Cyclic amine derivatives and their use as drugs |
| 07/13/2005 | EP1553080A1 Use of cyclic depsipeptide as a chemotherapeutic agent against cancer |
| 07/13/2005 | EP1553078A1 Calcium receptor-active compounds |
| 07/13/2005 | EP1553075A1 Lpa receptor antagonists |
| 07/13/2005 | EP1552857A1 Apparatus for dispensing medicaments |
| 07/13/2005 | EP1552851A1 Rapidly disintegrating tablet and process for producing the same |
| 07/13/2005 | EP1552850A2 A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| 07/13/2005 | EP1552849A1 Immunotherapeutic for cancer |
| 07/13/2005 | EP1552846A2 Use of heparinases to decrease inflammatory responses |
| 07/13/2005 | EP1552841A1 Arsenic sulfide compounds and derivates thereof for the treatment of malignancies |
| 07/13/2005 | EP1552839A1 Separate type medical material |
| 07/13/2005 | EP1552838A1 Rubrofusarin glycoside-containing composition |
| 07/13/2005 | EP1552837A1 Antipsoriatic agent |
| 07/13/2005 | EP1552836A1 Anti-neurodegenerative agents |
| 07/13/2005 | EP1552835A1 Transdermal patch for external use comprising fentanyl |
| 07/13/2005 | EP1552834A1 Neurotrophic factor production promoter |
| 07/13/2005 | EP1552833A1 Stable solid preparations |
| 07/13/2005 | EP1552832A1 Process for producing coated preparation |
| 07/13/2005 | EP1552831A1 Use of riluzole for treating multiple sclerosis |
| 07/13/2005 | EP1552830A1 Drug composition for prevention or inhibition of advance of diabetic complication |
| 07/13/2005 | EP1552828A1 Thrombopoetin receptor activator and process for producing the same |
| 07/13/2005 | EP1552827A1 Oral preventive/therapeutic agent for skin damage containing diacylglyceryl ether |
| 07/13/2005 | EP1552826A1 Amino acid compositions for improving central functions |
| 07/13/2005 | EP1552825A1 Therapeutic agent for overactive bladder |
| 07/13/2005 | EP1552824A1 Therapeutic agent for chronic obstructive pulmonary disease |
| 07/13/2005 | EP1552823A2 Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections |
| 07/13/2005 | EP1552822A1 Patch |
| 07/13/2005 | EP1552745A1 Therapeutic combinations of venous dilators and arterial dilators |
| 07/13/2005 | EP1552018A2 Methods and compositions relating to gene silencing |
| 07/13/2005 | EP1551983A2 Identification of e2f target genes and uses thereof |
| 07/13/2005 | EP1551962A2 Mitotic kinesin binding site |
| 07/13/2005 | EP1551873A1 Agonists and antagonists of the human odorant receptor or17-4 and uses thereof |
| 07/13/2005 | EP1551865A2 Hybrid molcules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules |
| 07/13/2005 | EP1551860A1 Glucocorticoid receptor ligands for the treatment of metabolic disorders |
| 07/13/2005 | EP1551853A1 Method for the separation of triglycoalkaloids |
| 07/13/2005 | EP1551850A1 2" oxo-voruscharin and derivatives thereof |
| 07/13/2005 | EP1551848A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 07/13/2005 | EP1551844A2 Antitumoral analogs of lamellarins |
| 07/13/2005 | EP1551842A1 Pyradazine compounds as gsk-3 inhibitors |
| 07/13/2005 | EP1551841A1 Pyrazolopyrimidines as kinase inhibitors |
| 07/13/2005 | EP1551840A1 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 07/13/2005 | EP1551839A1 Process for preparing 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine |
| 07/13/2005 | EP1551837A1 Phosphodiesterase 4 inhibitors |
| 07/13/2005 | EP1551835A1 Novel 1,4-diazabicycloalkane derivatives, their preparation and use |
| 07/13/2005 | EP1551834A1 Substituted quinazolinone compounds |
| 07/13/2005 | EP1551830A2 Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibators |
| 07/13/2005 | EP1551828A1 Pyrazole derivatives |
| 07/13/2005 | EP1551824A1 Protein tyrosine kinase inhibitors |
| 07/13/2005 | EP1551822A2 Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them |
| 07/13/2005 | EP1551818A1 Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands |
| 07/13/2005 | EP1551815A1 Thiazole compounds for the treatment of neurodegenerative disorders |
| 07/13/2005 | EP1551814A1 Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists |
| 07/13/2005 | EP1551813A2 Chemical compounds |